Cargando…

Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors

BACKGROUND: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte prec...

Descripción completa

Detalles Bibliográficos
Autores principales: Erickson-Miller, Connie L, Pillarisetti, Kodandaram, Kirchner, Jennifer, Figueroa, David J, Ottesen, Lone, Martin, Anne-Marie, Liu, Yuan, Kamel, Yasser Mostafa, Messam, Conrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480928/
https://www.ncbi.nlm.nih.gov/pubmed/22967017
http://dx.doi.org/10.1186/1471-2407-12-405
_version_ 1782247658783506432
author Erickson-Miller, Connie L
Pillarisetti, Kodandaram
Kirchner, Jennifer
Figueroa, David J
Ottesen, Lone
Martin, Anne-Marie
Liu, Yuan
Kamel, Yasser Mostafa
Messam, Conrad
author_facet Erickson-Miller, Connie L
Pillarisetti, Kodandaram
Kirchner, Jennifer
Figueroa, David J
Ottesen, Lone
Martin, Anne-Marie
Liu, Yuan
Kamel, Yasser Mostafa
Messam, Conrad
author_sort Erickson-Miller, Connie L
collection PubMed
description BACKGROUND: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte precursors, although little is known about its expression on other tissues. METHODS: Breast, lung, and ovarian tumor samples were analyzed for MPL expression by microarray and/or quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and for TPO-R protein expression by immunohistochemistry (IHC). Cell line proliferation assays were used to analyze the in vitro effect of eltrombopag on breast, lung, and ovarian tumor cell proliferation. The lung carcinoma cell lines were also analyzed for TPO-R protein expression by Western blot. RESULTS: MPL mRNA was not detectable in 118 breast tumors and was detectable at only very low levels in 48% of 29 lung tumors studied by microarray analysis. By qRT-PCR, low but detectable levels of MPL mRNA were detectable in some normal (14-43%) and malignant (3-17%) breast, lung, and ovarian tissues. A comparison of MPL to EPOR, ERBB2, and IGF1R mRNA demonstrates that MPL mRNA levels were far lower than those of EPOR and ERBB2 mRNA in the same tissues. IHC analysis showed negligible TPO-R protein expression in tumor tissues, confirming mRNA analysis. Culture of breast, lung, and ovarian carcinoma cell lines showed no increase, and in fact, showed a decrease in proliferation following incubation with eltrombopag. Western blot analyses revealed no detectable TPO-R protein expression in the lung carcinoma cell lines. CONCLUSIONS: Multiple analyses of breast, lung, and ovarian tumor samples and/or cell lines show no evidence of MPL mRNA or TPO-R protein expression. Eltrombopag does not stimulate growth of breast, lung, or ovarian tumor cell lines at doses likely to exert their actions on megakaryocytes and megakaryocyte precursors.
format Online
Article
Text
id pubmed-3480928
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34809282012-10-27 Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors Erickson-Miller, Connie L Pillarisetti, Kodandaram Kirchner, Jennifer Figueroa, David J Ottesen, Lone Martin, Anne-Marie Liu, Yuan Kamel, Yasser Mostafa Messam, Conrad BMC Cancer Research Article BACKGROUND: Numerous efficacious chemotherapy regimens may cause thrombocytopenia. Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia. The TPO-R MPL is expressed on megakaryocytes and megakaryocyte precursors, although little is known about its expression on other tissues. METHODS: Breast, lung, and ovarian tumor samples were analyzed for MPL expression by microarray and/or quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and for TPO-R protein expression by immunohistochemistry (IHC). Cell line proliferation assays were used to analyze the in vitro effect of eltrombopag on breast, lung, and ovarian tumor cell proliferation. The lung carcinoma cell lines were also analyzed for TPO-R protein expression by Western blot. RESULTS: MPL mRNA was not detectable in 118 breast tumors and was detectable at only very low levels in 48% of 29 lung tumors studied by microarray analysis. By qRT-PCR, low but detectable levels of MPL mRNA were detectable in some normal (14-43%) and malignant (3-17%) breast, lung, and ovarian tissues. A comparison of MPL to EPOR, ERBB2, and IGF1R mRNA demonstrates that MPL mRNA levels were far lower than those of EPOR and ERBB2 mRNA in the same tissues. IHC analysis showed negligible TPO-R protein expression in tumor tissues, confirming mRNA analysis. Culture of breast, lung, and ovarian carcinoma cell lines showed no increase, and in fact, showed a decrease in proliferation following incubation with eltrombopag. Western blot analyses revealed no detectable TPO-R protein expression in the lung carcinoma cell lines. CONCLUSIONS: Multiple analyses of breast, lung, and ovarian tumor samples and/or cell lines show no evidence of MPL mRNA or TPO-R protein expression. Eltrombopag does not stimulate growth of breast, lung, or ovarian tumor cell lines at doses likely to exert their actions on megakaryocytes and megakaryocyte precursors. BioMed Central 2012-09-11 /pmc/articles/PMC3480928/ /pubmed/22967017 http://dx.doi.org/10.1186/1471-2407-12-405 Text en Copyright ©2012 Erickson-Miller et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Erickson-Miller, Connie L
Pillarisetti, Kodandaram
Kirchner, Jennifer
Figueroa, David J
Ottesen, Lone
Martin, Anne-Marie
Liu, Yuan
Kamel, Yasser Mostafa
Messam, Conrad
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
title Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
title_full Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
title_fullStr Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
title_full_unstemmed Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
title_short Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
title_sort low or undetectable tpo receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480928/
https://www.ncbi.nlm.nih.gov/pubmed/22967017
http://dx.doi.org/10.1186/1471-2407-12-405
work_keys_str_mv AT ericksonmillerconniel loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT pillarisettikodandaram loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT kirchnerjennifer loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT figueroadavidj loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT ottesenlone loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT martinannemarie loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT liuyuan loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT kamelyassermostafa loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors
AT messamconrad loworundetectabletporeceptorexpressioninmalignanttissueandcelllinesderivedfrombreastlungandovariantumors